
VIVOS INC
100
Recent news coverage is largely unrelated to Vivos Inc.'s core business and focuses on broader market and commodity developments.
- No recent news directly related to Vivos Inc.'s business operations or developments was identified in the primary news sources [N1][N2][N3][N4][N5][N6][N7][N8].
Vivos Inc. develops and commercializes precision radionuclide therapy devices using yttrium-90 hydrogel technology for treating solid tumors in humans and animals. The company’s human therapy product, RadioGel®, is classified as a medical device by the FDA, enabling a streamlined regulatory process. Its veterinary counterpart, IsoPet®, is marketed for treating animal cancers and has seen rapid adoption and clinic certification growth. Vivos collaborates with national laboratories and veterinary hospitals for clinical validation and has established a subsidiary in India to support manufacturing, clinical trials, and commercialization. The company is actively pursuing FDA Investigational Device Exemption approval for human therapy and expanding production capabilities with new domestic and international manufacturing sites. Financially, Vivos maintains a strong liquidity position but reported a net loss in the most recent period.
Vivos Inc. is a medical device company specializing in yttrium-90 based precision radionuclide therapy for cancer treatment in humans and animals. The company markets RadioGel® for human oncology and IsoPet® for veterinary oncology, with FDA device classifications facilitating regulatory pathways. Vivos has demonstrated significant growth in its veterinary therapy division and is advancing human clinical trials, including regulatory submissions and manufacturing expansions in the US and India. Financially, as of September 30, 2026, the company reported $3.27 million in cash and equivalents, a strong liquidity position with a current ratio of 12.33, and a net loss of $731,594 for the nine months ended September 30, 2026. Financial figures are summarized from the latest SEC filings and provided for informational purposes only — not financial advice.
Vivos has demonstrated rapid growth in its veterinary therapy division with a 1,200% increase in administered therapies and expanding clinic certifications, indicating strong market acceptance. The company’s FDA Breakthrough Device designation and ongoing IDE submission efforts for human therapy suggest regulatory engagement and potential for future approvals. Establishing manufacturing facilities domestically and internationally could improve production scalability and reduce costs. The exploration of additional isotopes and expanded indications for use may broaden the therapeutic applications of its platform. Strategic initiatives in India support clinical development and commercialization in a large emerging market.
The company reported a net loss of $731,594 for the nine months ended September 30, 2026, indicating ongoing unprofitability. Regulatory approval processes remain complex and have encountered setbacks, including an FDA IDE rejection requiring resubmission and addressing detailed agency feedback. Manufacturing expansion plans depend on successful licensing and operational readiness, which may face delays. The company’s reliance on a niche technology and relatively early-stage commercial adoption in human therapy present execution risks. Market acceptance beyond veterinary applications is uncertain, and financial resources may be constrained given current losses.
Vivos Inc.’s moat derives from its proprietary yttrium-90 hydrogel technology for precision radionuclide therapy, which offers targeted radiation treatment with minimal exposure to surrounding tissues. The company benefits from FDA device classifications that facilitate regulatory pathways for both human and veterinary applications. Its collaborations with leading research institutions and veterinary hospitals provide clinical validation and procedural development, supporting adoption. The establishment of manufacturing facilities in the US and India aims to enhance supply chain resilience and cost efficiency. The dual focus on human and veterinary oncology markets, combined with ongoing clinical trials and regulatory engagement, contributes to a differentiated position in the niche of radionuclide cancer therapies.
• Regulatory Approval Risk: The FDA IDE submission for RadioGel® was rejected in August 2025 due to deficiencies, requiring resubmission and addressing extensive FDA feedback, which may delay commercialization.
• Manufacturing and Supply Chain Risk: The company is transitioning from a single contract manufacturer to multiple facilities in the US and India, which involves operational and licensing challenges that could impact production continuity.
• Financial Risk: Vivos reported a net loss and has limited disclosed revenue, indicating ongoing funding needs and potential liquidity constraints that could affect operations and growth.
• Market Adoption Risk: While veterinary therapy has shown rapid growth, human therapy adoption depends on regulatory approvals and clinical trial outcomes, which remain uncertain.
Business trends: Expansion of veterinary therapy adoption with significant growth and clinic certifications; ongoing human clinical trials and regulatory engagement; manufacturing facility development in US and India.
Execution milestones: FDA IDE resubmission addressing prior deficiencies; operational readiness of dual manufacturing sites; clinical trial progress in India; integration of veterinary clinical data to support human therapy.
Key risks: Regulatory approval delays and uncertainties; manufacturing scale-up and licensing challenges; financial losses and liquidity constraints; market adoption beyond veterinary applications.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Vivos Inc. is a radiation oncology medical device company developing yttrium-90 (Y-90) based precision radionuclide therapy devices for treating solid tumors in humans and animals [S1].
- The company markets RadioGel® for human therapy and IsoPet® for veterinary use, both based on the same Y-90 hydrogel technology [S1].
- RadioGel® is classified by the FDA as a device for human therapy for non-resectable cancers, facilitating a faster regulatory path than drugs [S1].
- IsoPet® is classified as a veterinary medical device by the FDA Center for Veterinary Medicine, allowing commercial distribution without premarket approval, provided compliance with safety and labeling requirements [S1].
- The company’s IsoPet Solutions division focuses on veterinary oncology, with significant growth including a 1,200% year-over-year increase in administered therapies from 2024 to 2025 and expansion of certified veterinary clinics [S1].
- Vivos has engaged multiple national laboratories and university veterinary hospitals for testing and therapy development, confirming safety and efficacy of the Y-90 hydrogel with minimal off-target radiation [S1].
- The company has initiated human clinical trials in India and established Vivos Scientific India LLP to support manufacturing, regulatory approvals, and commercialization in India [S1].
- Vivos is pursuing FDA Investigational Device Exemption (IDE) approval for RadioGel® as a Class II medical device, with ongoing interactions and resubmissions addressing FDA feedback [S1].
- The company plans to establish two production facilities in 2026: a domestic site in Richland, Washington, and an international site in India, to improve supply chain resilience and reduce costs [S1].
- Vivos is exploring additional isotopes (P-32, Lu-177, Ac-225) for future indications, targeting a broader range of cancers including lymph nodes, lung, brain, eyelid, and all solid tumors [S1].
- Financial snapshot as of September 30, 2026: cash and equivalents $3.27 million, current assets $1.91 million, current liabilities $0.16 million, current ratio 12.33, cash ratio 21.04, net loss $731,594 for the nine months ended September 30, 2026 [S2].
- Basic and diluted earnings per share were reported as zero for the period ending September 30, 2026 [S2].
- The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
Generated 2026-11-12
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Excessive Ivory Coast Rains Disrupt Cocoa Supplies and Boost Prices | https://www.nasdaq.com/articles/excessive-ivory-coast-rains-disrupt-cocoa-supplies-and-boost-prices
- N2 | 2026-11-12 | www.nasdaq.com | Cocoa Prices Jump as Excessive Rain in Ivory Coast Disrupts Supplies | https://www.nasdaq.com/articles/cocoa-prices-jump-excessive-rain-ivory-coast-disrupts-supplies
- N3 | 2026-11-12 | www.nasdaq.com | Stocks Slip as Nvidia Weakness Weighs on Chipmakers and AI Stocks | https://www.nasdaq.com/articles/stocks-slip-nvidia-weakness-weighs-chipmakers-and-ai-stocks
- N4 | 2026-11-12 | www.nasdaq.com | Valens Semiconductor Ltd. Reports Q3 2026 Revenue of $21.9 million | https://www.nasdaq.com/articles/valens-semiconductor-ltd-reports-q3-2026-revenue-219-million
- N5 | 2026-11-12 | www.nasdaq.com | InMode Ltd. Reports Third Quarter 2026 GAAP Revenues of $92.1 Million | https://www.nasdaq.com/articles/inmode-ltd-reports-third-quarter-2026-gaap-revenues-921-million
- N6 | 2026-11-12 | www.nasdaq.com | Applied Materials Q4 Profit Jumps 43% | https://www.nasdaq.com/articles/applied-materials-q4-profit-jumps-43
- N7 | 2026-11-12 | www.nasdaq.com | Canadian Stocks Move Lower, Weighed Down By Sharp Losses In The Materials Sector | https://www.nasdaq.com/articles/canadian-stocks-move-lower-weighed-down-sharp-losses-materials-sector
- N8 | 2026-11-12 | www.nasdaq.com | One Stop Systems Awarded New $1 Mln Defense Production Order For GNSS Testing | https://www.nasdaq.com/articles/one-stop-systems-awarded-new-1-mln-defense-production-order-gnss-testing
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


